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Abstract Pancreatic endocrine tumors (PET) are rare neo-
plasms classified as functioning (F-PET) or non-
functioning (NF-PET) according to the presence of a
clinical syndrome due to hormonal hypersecretion. PETs
show variable degrees of clinical aggressiveness and loss of
chromosome 3p has been suggested to be associated with
an advanced stage of disease. We assessed chromosome 3p
copy number in 113 primary PETs and 32 metastases by
fluorescence in situ hybridization (FISH) using tissue
microarrays. The series included 56 well-differentiated
endocrine tumors (WDET), 62 well-differentiated endo-
crine carcinomas (WDEC), and 6 poorly differentiated
endocrine carcinomas (PDEC). Chromosome 3p alterations
were found in 23/113 (20%) primary tumors, with losses
being predominant over gains (14% vs. 6%). Loss of 3p
was found in 5/55 (9%) WDET, 11/52 (21%) WDEC, and
never in PDEC. Gains of 3p were detected in 4/55 (7%)
WDET, no WDEC, but notably in 3/6 (50%) PDEC (OR
23.6; P=0.003). Metastases were more frequently monoso-
mic for 3p compared to primary tumors (OR 3.6; P=0.005).
Monosomy was significantly associated with larger tumor
size, more advanced tumor stage, and metastasis. No
association was found with survival. Chromosome 3p copy
number alterations are frequent events in advanced stage
PET, with gains prevailing in PDEC while losses are more
frequent in WDEC, supporting the view that a specific
pattern of alterations are involved in these diverse disease
subtypes.
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Introduction
Pancreatic endocrine tumors (PET) are rare neoplasms
whose molecular pathogenesis is being unraveled but is
still largely unknown [1–4]. PET are classified clinically as
functioning (F-PET) or non-functioning (NF-PET) accord-
ing to the presence of a syndrome due to hormonal
hypersecretion. NF-PET and F-PET other than insulinoma
are malignant in up to 70% of cases. The WHO
classification distinguishes three categories: well-
differentiated endocrine tumor having an indolent clinical
course; well-differentiated endocrine carcinoma (WDEC)
that is diagnosed based on the presence of invasion or
metastasis; poorly differentiated endocrine carcinoma
(PDEC) with a survival as poor as that of pancreatic
adenocarcinoma [5]. However, the malignant potential of
WDEC varies greatly and cannot be predicted by histolog-
ical appearance alone. Although the recently proposed
TNM staging and the proliferation rate of the neoplasia
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are valuable predictors of clinical outcome, additional
prognostic parameters are warranted [6, 7].
Chromosomal alterations have been suggested to be
prognostic parameters for tumor progression, recurrence,
and tumor-specific death in these tumors. In PETs, alter-
ations of 3p were investigated using two approaches: by
LOH microsatellite analysis, allelic imbalance at 3p was
observed in an average of 47% of cases [8–13] whereas by
means of comparative genomic hybridization (CGH), loss
of 3p was found in 21% of PETs [14–16]. Moreover, in
almost all studies investigating this subject, these alterations
were associated with an advanced stage of disease.
Potential candidate genes at this locus include VHL and
RASSF1A, that have been recently associated with PET
pathogenesis [12, 17–19]. Interestingly, recent data from
Schmitt et al. suggest that VHL inactivation and consecutive
hypoxia signals may be a mechanism for the development
of sporadic PET with an adverse outcome [17]. Moreover,
inactivation of the tumor suppressor gene RASSF1A by
hypermethylation and 3p LOH has been proposed as a
major event in PET tumorigenesis [12, 18, 19].
A large amount of evidences support the association of
3p alterations with prognosis, however the methods
previously employed to detect this association are not
easily applicable to clinical practice. Fluorescence in situ
hybridization (FISH) is commonly used as a diagnostic
device in cancer. Here, we explore the possibility to use
FISH on chromosome 3p as a prognostic tool for PET by
screening a large series composed of 113 PET and 32
metastases and correlating the results with clinical–
pathological features of patients.
Materials and methods
Samples
The series comprises 113 primitive neoplasms and 32
metastases obtained from 124 PET patients operated on at
the University Hospital of Verona, Italy. Of the metastases,
21 had a matched primary tumor in the series. Clinical–
pathological features of the present series are shown in
Table 1. Informed consent for the analysis of normal and
neoplastic tissues was obtained from patients, in accordance
with the approval of the Verona University and Hospital
Trust’s Ethical Committee.
Tissue microarrays
Six tissue microarrays (TMAs) containing the 113 primary
PETs and 32 metastases were constructed, using a tissue
arrayer (Beecher Instruments, Silver Spring, MD) and
including at least three cores of 1 mm diameter per sample [3].
Fluorescence in situ hybridization
FISH assay for chromosome 3pwas performed on 4-μm-thick
sections from TMAs, using a home-made SpectrumOrange
Parameter Categorya Frequency (percent)
Gender F 67 (54%)
M 57 (46%)
Age mean (1st quartile to 3rd quartile) 56 (44–65)
PT T1 34 (27%)
T2 33 (27%)
T3 21 (17%)
T4 36 (29%)
PN N0 74 (60%)
N1 50 (40%)
PM M0 85 (69%)
M1 39 (32%)
WHO PDEC 6 (5%)
WDEC 62 (50%)
WDET 56 (45%)
Hormone secretion Functioning 26 (21%)
Non-functioning 98 (79%)
Proliferative index Ki67>5% 28 (23%)
Ki67<5% 96 (77%)
Tumor size Mean (1st quartile to 3rd quartile) 30 (15–45)
Table 1 Clinical–pathological
features of 124 PETs consisting
of 113 primitive samples and 11
unmatched metastases
a PDEC poorly differentiated
endocrine carcinoma, WDEC
well-differentiated endocrine
carcinoma, WDET well-
differentiated tumor
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labeled DNA probe for the relevant region (Abbott-Vysis,
Downer Grove, IL, USA). Briefly, BAC clone specific for
chromosome 3p (RP11-894C9) mapping at 3p21.31 and
belonging to the Roswell Park Cancer Institute libraries
(Peter J. de Jong at http://bacpac.chori.org/) was selected.
Paraffin sections were hybridized with the probe labeled
by nick translation [20], using 500 ng of probe labeled
with Fluorolink Cy3-dUTP or Fluor-X-dCTP (Amersham,
Buckinghamshire, UK). For each sample, at least 110
nuclei were analyzed for presence of 3p signals.
Statistical analysis
k-means algorithm using Hartigan–Wong method was used
to classify PET samples into three classes, with no a priori
centroid definition, based on the distribution of FISH
counts. For sample assignation, 1,000 iterations were used.
For association of samples locus status with clinical–
pathological features, Fisher’s test was used. For correlation
of percent of PET cells showing monosomy with clinical–
pathological features, Kruskal–Wallis’ test was used for
categorical covariates and Spearman’s correlation for
numeric variables. Survival estimates were calculated with
Kaplan–Meier’s method and compared by the log-rank test.
P values less than 0.05 were considered significant. Where
applicable, the tests were two-tailed. For all the calcula-
tions, the R statistical software package was used (http://
www.r-project.org).
Results
FISH was performed on six TMAs containing 113 primary
PETs and 32 metastases. For each sample, we counted
neoplastic cells having one, two or more than two signals
per nucleus, for at least 110 cells per sample. Therefore, we
used the cell counts to assign samples to three unsupervised
classes, by the k-means algorithm. The centroids obtained
and distributions of the three classes are shown in Fig. 1.
The three classes were composed of 28 samples (19%) with
an excess of monosomic signals, 108 samples (75%) with a
predominant disomic state and 9 samples (6%) with
evidence of gains (Table 2).
Using such classification, we also found a high frequency
of samples showing gains among PDEC (3/6; OR 23.6;
95% CI 2.4–243.4; Fisher’s test P=0.003). In addition,
we found that monosomic samples were significantly more
represented in metastases (OR 3.6; 95% CI 1.3–9.6;
Fisher’s test P=0.005).
In order to investigate possible 3p alterations de novo
acquired in metastases, we compared the 3p status of 21
metastases with their matched primary samples (Table 3).
Thirteen patients had the same 3p copy number whereas in
three samples, the copy number increased and five showed
de novo losses.
As 3p loss was the most represented event, we then
focused on the correlation between losses and other
clinical–pathological covariates. In addition, to avoid
potential misclassification, the percent of monosomic cells
was directly used in the analysis instead of the categoriza-
tion introduced above. The results of this analysis are
summarized in Table 4. Percent of monosomic cells was
higher in metastases and positively correlated with larger
size, more advanced tumor invasion, carcinoma of the well-
differentiated type and absence of hormone secretions.
Although correlated with worse patients' outcome, we did
not find a significant association between monosomy and
survival, even when considering only the WDEC group.
Similarly, we did not find any significant association
between gains of 3p and survival.
Discussion
Several studies employing two main molecular approaches
(LOH by microsatellites and CGH) have suggested a role
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A B CFig. 1 Distribution of frequencyof neoplastic nuclei with one, two
or at least three FISH signals of
PET cases belonging to the
classes of monosomic (a),
disomic (b), gains (c), based on
the frequency of signals per
nucleus. The samples were
assigned to the three classes
using k-means algorithm
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for alterations of chromosome 3p in PET. A detailed survey
of the relevant literature has been collected in Table 5. In
particular, a relationship between LOH at 3p and locally
advanced or metastatic PETs was found in all previous
works. Of the two techniques used, LOH detected consis-
tently a higher number of alterations [8–13] compared to
CGH [14–16] (47% vs. 21%). This apparent discrepancy
can be accounted for by the intrinsic features of the two
methods. In fact, although LOH by microsatellites provides
the ability to finely map the region where the alterations
occur, it sums up gains and losses that are difficult to tell
apart as both are seen as allelic imbalances. On the other
hand, with CGH only true losses are reported.
Our study showed that a consistent number of chromo-
somal alterations, detected by FISH, involved the 3p locus
with losses predominant over gains (14% vs. 6%). The use of
FISH allows the characterization of chromosomal alterations
at specific loci with a small cost per sample and avoids
artifacts deriving from analysis with other molecular techni-
ques such as LOH microsatellite analysis. Our results are
more in line with previous CGH reports, probably due to the
ability of both techniques to discern losses and gains.
In our series, we found that monosomic samples were
significantly more represented in metastases than in
primitive samples, in agreement with all previous studies
reporting a higher frequency of 3p loss in association with
metastatic event (see Table 5). Furthermore, in pair-wise
analysis of 21 matched primaries and metastases, we
observed that 3p copy number was conserved from
primitive to metastasis in 13 samples. However, five
metastases showed a decrease in 3p copy number; in two
patients, primitive samples were monosomic and metastasis
showed a disomic state, and one patient had a gain in
metastasis. This suggests the occurrence of tumor hetero-
geneity in PET and as such a role in their metastasis
formation mechanism.
In addition, we found that the proportion of monosomic
cells was positively correlated with non-functioning
status, larger size, a diagnosis of carcinoma of the well-
differentiated type and a more advanced pT stage. The
higher percent of monosomy found in non-functioning
PET was already suggested by previous studies describ-
ing this class of PET as having both larger size and
higher rate of chromosomal aberrations compared to the
functioning ones [8, 10, 16]. These data suggest that 3p
monosomy may occur later during the development of
disease and may contribute to the progression of malig-
nancy of PET. Although correlated with worse patient
features, we did not find a significant association between
monosomy and survival, also when considering only the
WDEC group, probably due to the general high survival
rate of PET.
Interestingly, several data support the role of genes
mapping on 3p in PET pathogenesis and malignancy.
Among these genes, VHL is a major candidate as patients
with Von-Hippel Lindau syndrome may develop pancreatic
endocrine tumors. Schmitt and colleagues have investigated
the presence of genetic and epigenetic alterations at VHL
locus in PETs [17]. By using FISH, they detected a
frequency of 3p loss of 18%, a number that is very close
to that found in our series. They suggest that VHL
inactivation and consecutive hypoxia signals may be a
mechanism for the development of sporadic PET with an
adverse outcome. However, another study identified LOH
Sample type WHO classificationa DNA copy number
1 2 3+
Primitive PDEC 0 3 (50%) 3 (50%)
WDEC 11 (21%) 41 (79%) 0
WDET 5 (9%) 46 (84%) 4 (7%)
Functioning 2 (9%) 18 (82%) 2 (9%)
Non-functioning 14 (15%) 72 (79%) 5 (6%)
Total 16 (14%) 90 (80%) 7 (6%)
Metastasis PDEC 0 2 (67%) 1 (33%)
WDEC 12 (41%) 16 (55%) 1 (3%)
Functioning 2 (40%) 3 (60%) 0
Non-functioning 10 (37%) 15 (56%) 2 (7%)
Total 12 (38%) 18 (56%) 2 (6%)
Table 2 Frequency of DNA
copy number status among 113
primitive PETs and 32
metastases
a PDEC poorly differentiated
endocrine carcinomas, WDEC
well-differentiated endocrine
carcinomas, WDET, well-
differentiated tumors
Table 3 DNA copy number of 3p in 21 primitive samples and their
matched metastases
Primitive copy number Metastases copy number
1 2 3+
1 3 2 0
2 5 9 1
3+ 0 0 1
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in an area outside the VHL gene (3p14.2–3p21), in 83% of
malignant insulinomas compared with 53% of benign
insulinomas [11], suggesting that other candidates are also
likely to be involved in PET onset and progression. Another
hypothesis suggests the presence of a novel pancreatic
endocrine tumor suppressor gene at 3p25, being the
frequency of 3p loss about 33% in the region flanking the
VHL gene. Allelic loss of this chromosomal region has been
Table 5 Summary of 3p LOH data available in literature for PET
No. of Cases 3p LOH (total) WHOa Tumor typeb Metastasis Methodc Reference
WDET WDEC F NF No Yes
10 3/10 0/5 3/5 nr nr 0/5 3/5 ms [12]
30% 0% 60% – – 0% 60%
82 47/82 7/25 40/57 24/47 23/35 17/41 28/38 ms [8]
57% 28% 70% 51% 65% 41.5% 74%
20 9/20 1/8 8/12 0/11 9/9 0/6 9/12 ms [10]
45% 12.5% 67% 0% 100% 0% 75%
43 14/43 2/22 12/21 11/29 3/14 2/22 12/21 ms [9]
33% 9% 57% 38% 21% 9% 57%
21 13/21 8/15 5/6 13/21 none 8/15 5/6 ms [11]
62% 53% 83% 62% – 53% 83%
16 5/16 2/8 3/8 none 5/16 2/9 3/7 ms [13]
31% 25% 37.5% – 31% 22% 30%
192 91/192 20/83 71/109 48/108 40/74 29/98 60/89 Total LOH by ms
47% 24% 65% 44% 54% 30% 67%
44 13/44 6/9 7/35 nr nr 2/22 10/18 CGH [15]
30% 67% 20% – – 9% 56%
45 9/45 3/28 6/17 5/31 4/14 3/28 6/17 CGH [16]
20% 11% 35% 16% 29% 11% 35%
20 1/20 0/8 1/12 none 1/20 0/9 1/11 CGH [14]
5% 0% 8% – 5% 0% 9%
109 23/109 9/45 14/64 5/31 5/34 5/59 17/46 Total LOH by CGH
21% 20% 22% 16% 15% 8% 37%
aWDEC well-differentiated endocrine carcinoma, WDET well-differentiated endocrine tumor
b F functioning, NF non-functioning
cms LOH by microsatellite analysis
nr not reported
Parameter Class Median (1st quartile to 3rd quartile) P value
Primitives 0.19 (0.14–0.25) <0.001
Metastases 0.26 (0.22–0.41)
pT T1 0.15 (0.13–0.23) 0.027
T2 0.18 (0.15–0.22)
T3 0.22 (0.16–0.27)
T4 0.23 (0.17–0.32)
pN N0 0.19 (0.14–0.25) 0.704
N1 0.20 (0.14–0.24)
pM M0 0.19 (0.14–0.24) 0.095
M1 0.22 (0.16–0.28)
WHO PDEC 0.11 (0.08–0.13) <0.001
WDEC 0.18 (0.13–0.21)
WDET 0.16 (0.14–0.24)
Hormone secretion Functioning 0.15 (0.11–0.21) 0.029
Non-functioning 0.20 (0.15–0.27)
Tumor size 0.30 (Spearman’s rho) 0.002
Ki67 0.05 (Spearman’s rho) 0.596
Table 4 Distribution of percent
of monosomy according to
clinical–pathological features of
113 primary pancreatic
endocrine tumors
PDEC poorly differentiated
endocrine carcinoma, WDEC
well-differentiated endocrine
carcinoma, WDET well-
differentiated tumor
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proposed to serve as a molecular marker discriminating
benign from clinically malignant disease [9].
Also, Barghorn et al. identified a common deleted region
(3p25-p24.2) in PETs that does not include VHL and
propose a new member of the nuclear receptor superfamily,
the peroxisome proliferator-activated receptor gamma
(PPARγ), as a possible candidate tumor suppressor [8].
Indeed, this gene has been demonstrated to act as a
regulator of differentiation and/or growth of many different
cell types [21, 22] and loss-of-function of mutations in
PPARγ have already been identified in human colon cancer
[23]. Another candidate gene on chromosome 3p is the
tumor suppressor gene RASSF1A that has been suggested to
be inactivated by 3p LOH and hypermethylation in 30% of
malignant well-differentiated carcinomas of the pancreas
[12]. In light of the association of 3p loss with malignancy,
we can underline the relevance of the pattern of 3p allelic
losses during progression of PET. However, the specific
targets of such alterations and their functional meaning in
PET tumorigenesis remain to be further investigated.
Notably, we found a higher proportion of gains in PDEC
with respect to WDEC, suggesting that this feature is
characteristic of poorly differentiated tumors. We did not
find any significant association between gains of 3p and
survival, although it is worth noting that none of the seven
patients showing gains (including the three PDECs) died of
disease, suggesting that gain of 3p could be a positive
prognostic factor.
Previous papers have demonstrated the presence of gain
of 3p in different types of cancer such as hepatocarcinoma
[24] and ductal carcinoma of the breast [25], but this feature
has never been observed in pancreatic endocrine tumors.
The reason may be probably due to the fact that poorly
differentiated carcinomas are rarely included in PET
studies. Therefore, based on our evidences, we cannot
hypothesize any potential oncogene that could be a target
for this kind of alteration.
As a methodological remark, we found that percent of
monosomic cells showed more power in detecting
association with clinical–pathological features, compared
to a discrete classification based on 3p copy number. The
reason for such a greater power may be due to the
inherent higher precision of a quantitative measure as it
can more finely reflect intermediate status, along the
tumor development path, in which the neoplastic popula-
tion is composed of genetically different clones with
different selective advantages.
In conclusion, our data showed that alterations in 3p
copy number may play an important role in tumor
progression, malignant behavior and metastasis and may
occur as a later event in cancer development. In addition,
we found that losses and gains of 3p locus are associated
with different forms of the disease: namely, gains with
poorly differentiated endocrine carcinoma, losses with well-
differentiated endocrine carcinoma. These data together
confirm that 3p may contain genes important for metastatic
development of PETs, but the specific targets as well as the
prognostic potential of these alterations need to be further
investigated.
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